ActivePhase 2ACTRN12607000402448

Autologous Tenocytes Therapy to Improve the Healing Process of Tennis Elbow – A Preliminary Clinical Trail

Autologous Tenocytes Therapy to Improve the Healing Process of Tennis Elbow


Sponsor

Orthocell Pty Ltd

Enrollment

30 participants

Start Date

Aug 15, 2007

Study Type

Interventional

Conditions

Summary

The aim of this study is to assess the potential role of autologous tenocytes therapy in the healing process of tennis elbow.


Eligibility

Sex: Both males and femalesMin Age: 30 YearssMax Age: 75 Yearss

Plain Language Summary

Simplified for easier understanding

This study investigates Autologous Tenocytes Therapy to Improve the Healing Process of Tennis Elbow – A Preliminary Clinical Trail. It is open to both men and women, aged 30 to 75. If you are interested, you may need to attend study visits and follow the research team's instructions.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Autologous Tenocytes Injection Autologous tenocytes will be digested from a small epitendineum tissue (connective tissue on the surface of tendon) harvested from patients’ patellar tendon. After a pe

Autologous Tenocytes Injection Autologous tenocytes will be digested from a small epitendineum tissue (connective tissue on the surface of tendon) harvested from patients’ patellar tendon. After a period of in vivo cultivation, 2ml of autologous tenocytes at concentration of 3X106cell/ml will be inject into the elbow site where feel most pain.Patients will be rescheduled for follow-up appointment at 4 and 12 weeks after the injection. During any stage of this study, patients are obligation free to leave the experiment. Those chosen to leave will be referral to standard treatment.


Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12607000402448


Related Trials